A San Diego-based company, Replicate Bioscience, has been awarded a grant from the Gates Foundation for the development of self-replicating RNA (srRNA) vaccine candidates targeted at tuberculosis. The grant is subject to humanitarian licensing terms. Replicate Bioscience, known for its innovative srRNA technology, is currently in the clinical stage of research. The funding from the Gates Foundation underscores the significance of this project in combating tuberculosis. The grant amount and duration were not disclosed in the news release.